OrbiMed’s Ultragenyx Pharmaceutical RARE Stock Holding History

OrbiMed’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-227,600	Closed	-$16.5M	–	150
2022 Q1	$16.5M	Buy	+227,600	New	+$15.8M	0.27%	76
2019 Q4	–	Sell	-834,313	Closed	-$35.7M	–	143
2019 Q3	$35.7M	Buy	834,313 +754,706	+948%	+$41M	0.68%	45
2019 Q2	$5.05M	Buy	+79,607	New	+$5.07M	0.08%	112
2018 Q3	–	Sell	-67,605	Closed	-$5.2M	–	158
2018 Q2	$5.2M	Buy	+67,605	New	+$4.37M	0.06%	127
2017 Q1	–	Sell	-169,300	Closed	-$11.9M	–	143
2016 Q4	$11.9M	Hold	169,300	–	–	0.15%	87
2016 Q3	$12M	Hold	169,300	–	–	0.14%	95
2016 Q2	$8.28M	Buy	169,300 +41,000	+32%	+$2.65M	0.09%	99
2016 Q1	$8.12M	Buy	+128,300	New	+$8.4M	0.09%	102

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed's RARE Position: Q2 2022 in Review

OrbiMed sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 227,600 shares — an estimated $16.5M sold.

OrbiMed first reported a position in RARE in Q1 2016 and held it in 8 quarters. The position peaked at $35.7M in Q3 2019. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

OrbiMed reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
OrbiMed sold 227,600 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $16.5M.
OrbiMed first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 8 quarters.
OrbiMed's Ultragenyx Pharmaceutical position peaked at $35.7M in Q3 2019.
223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.